Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, Akhtar OS, Auletta JJ, Huppler AR, Abid MB, CIBMTR

Open source

DOI: 10.1016/j.jtct.2026.06.029
Published: 2026 Jun 27
Container: Transplantation and cellular therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtct.2026.06.029,
  title = {Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.},
  author = {Wudhikarn K and Gowda L and Ye Q and Oloyede T and Martens M and Banerjee R and Devarakonda SS and Liu H and Herr MM and Young JH and Jain T and Dias A and Nishihori T and Mirza AS and Ganguly S and Beitinjaneh AM and Aljurf M and Wirk B and Farhadfar N and Efebera YA and Perales MA and Ebens CL and Murthy HS and Hill JA and Dandoy CE and Hong S and Boghdadly ZE and Akhtar OS and Auletta JJ and Huppler AR and Abid MB and CIBMTR},
  year = {2026},
  journal = {Transplantation and cellular therapy},
  doi = {10.1016/j.jtct.2026.06.029},
  url = {https://doi.org/10.1016/j.jtct.2026.06.029}
}

RIS

TY  - JOUR
TI  - Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.
AU  - Wudhikarn K
AU  - Gowda L
AU  - Ye Q
AU  - Oloyede T
AU  - Martens M
AU  - Banerjee R
AU  - Devarakonda SS
AU  - Liu H
AU  - Herr MM
AU  - Young JH
AU  - Jain T
AU  - Dias A
AU  - Nishihori T
AU  - Mirza AS
AU  - Ganguly S
AU  - Beitinjaneh AM
AU  - Aljurf M
AU  - Wirk B
AU  - Farhadfar N
AU  - Efebera YA
AU  - Perales MA
AU  - Ebens CL
AU  - Murthy HS
AU  - Hill JA
AU  - Dandoy CE
AU  - Hong S
AU  - Boghdadly ZE
AU  - Akhtar OS
AU  - Auletta JJ
AU  - Huppler AR
AU  - Abid MB
AU  - CIBMTR
PY  - 2026
JO  - Transplantation and cellular therapy
DO  - 10.1016/j.jtct.2026.06.029
UR  - https://doi.org/10.1016/j.jtct.2026.06.029
ER  -

APA

K, W., L, G., Q, Y., T, O., M, M., R, B., SS, D., H, L., MM, H., JH, Y., T, J., A, D., T, N., AS, M., S, G., AM, B., M, A., B, W., N, F., YA, E., MA, P., CL, E., HS, M., JA, H., CE, D., S, H., ZE, B., OS, A., JJ, A., AR, H., MB, A., & CIBMTR (2026). Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.. Transplantation and cellular therapy. https://doi.org/10.1016/j.jtct.2026.06.029

Source records

pubmed · retrieved 2026-09-26T22:39:01.747Z